IL6 & 8 in Malnourished Children With Acute Diarrhea
ClinicalTrials.gov ID NCT05183789
Sponsor Sohag University
Information provided by Motaz Mohamed Hassan, Sohag University (Responsible Party)
Assessment of FOXP3 Gene Polymorphisms and Serum Interleukin 10 in Patients With ITP (FoxP3ITP)
ClinicalTrials.gov ID NCT05410249
Sponsor Sohag University
Information provided by Noha Saber Shafik, Sohag University (Responsible Party)
Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP (RECAP-5)
ClinicalTrials.gov ID NCT05672030
Sponsor Brigham and Women’s Hospital
Information provided by Tanya Laidlaw, MD, Brigham and Women’s Hospital (Responsible Party)
October 12, 2023 By Marta Catalfamo
Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (DiTuSarc)
ClinicalTrials.gov Identifier: NCT05080790
Recruitment Status : Recruiting
First Posted : October 18, 2021
Last Update Posted : June 3, 2022
See Contacts and Locations
Serum Interleukin – 17A in Juvenile Idiopathic Arthritis
ClinicalTrials.gov Identifier: NCT05688358
Recruitment Status : Not yet recruiting
First Posted : January 18, 2023
Last Update Posted : January 18, 2023
See Contacts and Locations
Beta Endorphins,Interleukin 1 and Interleukin 38 in Covid Patients Associated With Neuropsychological Manifestations.
ClinicalTrials.gov Identifier: NCT05198388
Recruitment Status : Recruiting
First Posted : January 20, 2022
Last Update Posted : January 25, 2022
See Contacts and Locations
THE VALUE OF INTERLEUKIN 6 AS A DIAGNOSTIC MARKER IN NEONATAL SEPSIS
ClinicalTrials.gov Identifier: NCT05585957
Recruitment Status : Not yet recruiting
First Posted : October 19, 2022
Last Update Posted : October 19, 2022
See Contacts and Locations
Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy
ClinicalTrials.gov Identifier: NCT04911166
Recruitment Status : Recruiting
First Posted : June 2, 2021
Last Update Posted : April 24, 2023
See Contacts and Locations
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
ClinicalTrials.gov Identifier: NCT03030378
Recruitment Status : Recruiting
First Posted : January 25, 2017
Last Update Posted : September 28, 2023
See Contacts and Locations
Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease (IMPULSE-7)
ClinicalTrials.gov Identifier: NCT04154826
Recruitment Status : Recruiting
First Posted : November 7, 2019
Last Update Posted : March 31, 2022
See Contacts and Locations
Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera
ClinicalTrials.gov Identifier: NCT03882307
Recruitment Status : Recruiting
First Posted : March 20, 2019
Last Update Posted : July 26, 2022
See Contacts and Locations
Performance of Interleukin-27 Cord Blood Level as A Biomarker Predicating Early Onset Neonatal Sepsis
ClinicalTrials.gov Identifier: NCT05589909
Recruitment Status : Recruiting
First Posted : October 21, 2022
Last Update Posted : October 21, 2022
See Contacts and Locations
Estimation of the Tissue and Serum Levels of Interleukin (IL) -35 in Mycosis Fungoides: a Case Control Study
ClinicalTrials.gov Identifier: NCT05855460
Recruitment Status : Recruiting
First Posted : May 11, 2023
Last Update Posted : May 11, 2023
See Contacts and Locations
Low Dose IL-2 for the Treatment of Crohn’s Disease
ClinicalTrials.gov Identifier: NCT04263831
Recruitment Status : Recruiting
First Posted : February 11, 2020
Last Update Posted : July 18, 2023
See Contacts and Locations
Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis (MAGiC-ART)
ClinicalTrials.gov Identifier: NCT04017936
Recruitment Status : Recruiting
First Posted : July 12, 2019
Last Update Posted : November 7, 2023
See Contacts and Locations
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ) (ILIAD-7-US-O)
ClinicalTrials.gov Identifier: NCT04426201
Recruitment Status : Active, not recruiting
First Posted : June 11, 2020
Last Update Posted : April 8, 2022
Interleukin-34 Level in Periodontal Disease
ClinicalTrials.gov Identifier: NCT05962567
Recruitment Status : Recruiting
First Posted : July 27, 2023
Last Update Posted : July 27, 2023
See Contacts and Locations
Urine Interleukin-37 as a Biomarker of Mortality Risk in Patients With Sepss
ClinicalTrials.gov Identifier: NCT05640037
Recruitment Status : Recruiting
First Posted : December 7, 2022
Last Update Posted : June 28, 2023
See Contacts and Locations
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
ClinicalTrials.gov Identifier: NCT05094570
Recruitment Status : Recruiting
First Posted : October 26, 2021
Last Update Posted : November 30, 2023
See Contacts and Locations
Interferon Alpha Therapy for Cervical CINI and HPV Infection
ClinicalTrials.gov Identifier: NCT06137950
Recruitment Status : Recruiting
First Posted : November 18, 2023
Last Update Posted : November 18, 2023
See Contacts and Locations
Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients (IGNORANT)
ClinicalTrials.gov Identifier: NCT05843786
Recruitment Status : Recruiting
First Posted : May 6, 2023
Last Update Posted : September 14, 2023
See Contacts and Locations
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia
ClinicalTrials.gov Identifier: NCT04226950
Recruitment Status : Recruiting
First Posted : January 13, 2020
Last Update Posted : November 15, 2023
See Contacts and Locations
Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
ClinicalTrials.gov Identifier: NCT04979052
Recruitment Status : Recruiting
First Posted : July 27, 2021
Last Update Posted : November 3, 2023
See Contacts and Locations
To Evaluate the Clinical Efficacy and Safety of Recombinant Human Interferon ω Spray in Treatment of Viral Upper Respiratory Tract Infection in Children
ClinicalTrials.gov Identifier: NCT05859984
Recruitment Status : Not yet recruiting
First Posted : May 16, 2023
Last Update Posted : May 16, 2023
See Contacts and Locations
Impact of the Presence of Anti-interferon Autoantibodies on the Viral Load in Severe Respiratory Infections (INTERFERICUS)
ClinicalTrials.gov Identifier: NCT05536219
Recruitment Status : Recruiting
First Posted : September 10, 2022
Last Update Posted : November 18, 2023
See Contacts and Locations
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden (INFORM)
ClinicalTrials.gov Identifier: NCT06053749
Recruitment Status : Not yet recruiting
First Posted : September 26, 2023
Last Update Posted : November 18, 2023
See Contacts and Locations
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
ClinicalTrials.gov Identifier: NCT03120624
Recruitment Status : Recruiting
First Posted : April 19, 2017
Last Update Posted : November 15, 2023
See Contacts and Locations
Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis
ClinicalTrials.gov Identifier: NCT05953545
Recruitment Status : Not yet recruiting
First Posted : July 20, 2023
Last Update Posted : November 30, 2023
See Contacts and Locations
TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma (TUNINTIL)
Principal Investigators: Inge Marie Svane, MD. CCIT, Herlev Hospital, Copenhagen University. Copenhagen, Denmark
Contact:. Inge Marie Svane, MD. Phone: +45 38 68 38 68
ClinicalTrials.gov Identifier: NCT04217473
Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (DiTuSarc)
Principal Investigators: Peter Reichardt, MD. Helios Klinikum Berlin-Buch. Berlin, Germany, 13125
Contact: Daniel Pink, MD. Phone: 033631 73527
ClinicalTrials.gov Identifier: NCT05080790
Targeting IL-17A for Treatment-Resistant Depression
Principal Investigators: James W Murrough, MD, PhD. Icahn School of Medicine at Mount Sinai. New York, New York, United States, 10025
Contact: Mirabel Sleiman, BA. Phone: +1 212-585-6136
ClinicalTrials.gov Identifier: NCT04979910
Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate (TRANSFORM)
Principal Investigators: Atsushi Kawakami, MD, PhD. Nagasaki University Hospital. Nagasaki, Japan, 852-8501.
Contact: Atsushi Kawakami, MD, PhD. Phone: +81-95-819-7260
ClinicalTrials.gov Identifier: NCT05090410
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer
Principal Investigators: Xiuning Le, MD, PhD. MD Anderson Cancer Center. Houston, Texas, United States, 77030.
Contact: Xiuning Le, MD, PhD. Phone: +1 713-792-6980
ClinicalTrials.gov Identifier: NCT05704634
Pharmacogenetic Studies on Anti-IL-6 Receptor Monoclonal Antibodies on the Treatment of Rheumatic Diseases
Principal Investigators: Luis Sainz, MD. Hospital de la Santa Creu i Sant Pau. Barcelona, Spain, 08041
Contact: Luis Sainz, MD. Phone: +34 679743541 ext +34
ClinicalTrials.gov Identifier: NCT05045001
Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
Principal Investigators: Maria Vehreschild, Prof. Klinikum Der Johann Wolfgang Von Goethe Universitaet. Frankfurt am main, Germany, 60590
Contact: Frank vd Veerdonk, Dr. Phone: 0031243618819
ClinicalTrials.gov Identifier: NCT04979052
Impact of the Presence of Anti-interferon Autoantibodies on the Viral Load in Severe Respiratory Infections
Principal Investigators: Louis CHAUVELOT, MD. Hopital Lyon Sud. Pierre-Bénite, Rhone, France, 69110
Contact: Florent Wallet, MD Phone: 0478861921 ext +33
ClinicalTrials.gov Identifier: NCT05536219
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Principal Investigators: Jennifer Eva Selfridge, MD, PhD. University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center. Cleveland, Ohio, United States, 44106
Contact: Jennifer E. Selfridge, MD, PhD. Phone: 18006412422
ClinicalTrials.gov Identifier: NCT05400122
Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV
Principal Investigators: Jose H. Lincona, MD. Brigham and Women’s Hospital Vaccine CRS [30007]. Boston, Massachusetts, United States, 02115
Contact: Jose H. Lincona, MD. Phone: 617-525-9433
ClinicalTrials.gov Identifier: NCT05781542
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio)
Principal Investigators: Jo Lambert, MD, PhD. Ghent University Hospital. Gent, Belgium, 9000
Contact: Juul van den Reek, MD, PhD. Phone: 0031243613724
ClinicalTrials.gov Identifier: NCT04340076
Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease (IMPULSE-7)
Principal Investigators: Andrej SPEC, MD. Washington University. Saint Louis, Missouri, United States, 63110
Contact: Michel MORRE, DVM. Phone: +33603357060
ClinicalTrials.gov Identifier: NCT04154826